vs
Side-by-side financial comparison of Gilead Sciences (GILD) and TJX Companies (TJX). Click either name above to swap in a different company.
TJX Companies is the larger business by last-quarter revenue ($15.1B vs $7.9B, roughly 1.9× Gilead Sciences). Gilead Sciences runs the higher net margin — 27.5% vs 9.5%, a 18.0% gap on every dollar of revenue. On growth, TJX Companies posted the faster year-over-year revenue change (7.5% vs 4.7%). Gilead Sciences produced more free cash flow last quarter ($3.1B vs $1.0B). Over the past eight quarters, Gilead Sciences's revenue compounded faster (8.9% CAGR vs -4.0%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
The TJX Companies, Inc. is an American multinational off-price department store corporation, headquartered in Framingham, Massachusetts. It was formed as a subsidiary of Zayre Corp. in 1987, and became the legal successor to Zayre Corp. following a company reorganization in 1989.
GILD vs TJX — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $15.1B |
| Net Profit | $2.2B | $1.4B |
| Gross Margin | 79.5% | 32.6% |
| Operating Margin | 25.0% | — |
| Net Margin | 27.5% | 9.5% |
| Revenue YoY | 4.7% | 7.5% |
| Net Profit YoY | 22.4% | 11.2% |
| EPS (diluted) | $1.75 | $1.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.9B | $15.1B | ||
| Q3 25 | $7.8B | $14.4B | ||
| Q2 25 | $7.1B | $13.1B | ||
| Q1 25 | $6.7B | $16.4B | ||
| Q4 24 | $7.6B | $14.1B | ||
| Q3 24 | $7.5B | $13.5B | ||
| Q2 24 | $7.0B | $12.5B | ||
| Q1 24 | $6.7B | $16.4B |
| Q4 25 | $2.2B | $1.4B | ||
| Q3 25 | $3.1B | $1.2B | ||
| Q2 25 | $2.0B | $1.0B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.8B | $1.3B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B | ||
| Q1 24 | $-4.2B | $1.4B |
| Q4 25 | 79.5% | 32.6% | ||
| Q3 25 | 79.8% | 30.7% | ||
| Q2 25 | 78.8% | 29.5% | ||
| Q1 25 | 76.9% | 30.5% | ||
| Q4 24 | 79.1% | 31.6% | ||
| Q3 24 | 79.1% | 30.4% | ||
| Q2 24 | 77.8% | 30.0% | ||
| Q1 24 | 76.8% | 29.8% |
| Q4 25 | 25.0% | — | ||
| Q3 25 | 42.8% | — | ||
| Q2 25 | 34.9% | — | ||
| Q1 25 | 33.6% | 11.6% | ||
| Q4 24 | 32.4% | 12.3% | ||
| Q3 24 | 11.8% | 10.9% | ||
| Q2 24 | 38.0% | 11.1% | ||
| Q1 24 | -64.6% | 11.2% |
| Q4 25 | 27.5% | 9.5% | ||
| Q3 25 | 39.3% | 8.6% | ||
| Q2 25 | 27.7% | 7.9% | ||
| Q1 25 | 19.7% | 8.6% | ||
| Q4 24 | 23.6% | 9.2% | ||
| Q3 24 | 16.6% | 8.2% | ||
| Q2 24 | 23.2% | 8.6% | ||
| Q1 24 | -62.4% | 8.5% |
| Q4 25 | $1.75 | $1.28 | ||
| Q3 25 | $2.43 | $1.10 | ||
| Q2 25 | $1.56 | $0.92 | ||
| Q1 25 | $1.04 | $1.23 | ||
| Q4 24 | $1.43 | $1.14 | ||
| Q3 24 | $1.00 | $0.96 | ||
| Q2 24 | $1.29 | $0.93 | ||
| Q1 24 | $-3.34 | $1.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | $4.6B |
| Total DebtLower is stronger | $24.9B | — |
| Stockholders' EquityBook value | $22.7B | $9.4B |
| Total Assets | $59.0B | $35.2B |
| Debt / EquityLower = less leverage | 1.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.0M | $4.6B | ||
| Q3 25 | $19.0M | $4.6B | ||
| Q2 25 | $69.0M | $4.3B | ||
| Q1 25 | — | $5.3B | ||
| Q4 24 | — | $4.7B | ||
| Q3 24 | — | $5.3B | ||
| Q2 24 | — | $5.1B | ||
| Q1 24 | — | $5.6B |
| Q4 25 | $24.9B | — | ||
| Q3 25 | $24.9B | — | ||
| Q2 25 | $24.9B | — | ||
| Q1 25 | $25.0B | — | ||
| Q4 24 | $26.7B | — | ||
| Q3 24 | $23.2B | — | ||
| Q2 24 | $23.3B | — | ||
| Q1 24 | $25.2B | — |
| Q4 25 | $22.7B | $9.4B | ||
| Q3 25 | $21.5B | $8.9B | ||
| Q2 25 | $19.7B | $8.5B | ||
| Q1 25 | $19.2B | $8.4B | ||
| Q4 24 | $19.3B | $8.2B | ||
| Q3 24 | $18.5B | $7.8B | ||
| Q2 24 | $18.3B | $7.5B | ||
| Q1 24 | $17.5B | $7.3B |
| Q4 25 | $59.0B | $35.2B | ||
| Q3 25 | $58.5B | $32.9B | ||
| Q2 25 | $55.7B | $31.9B | ||
| Q1 25 | $56.4B | $31.7B | ||
| Q4 24 | $59.0B | $32.4B | ||
| Q3 24 | $54.5B | $30.6B | ||
| Q2 24 | $53.6B | $29.7B | ||
| Q1 24 | $56.3B | $29.7B |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.16× | — | ||
| Q2 25 | 1.27× | — | ||
| Q1 25 | 1.30× | — | ||
| Q4 24 | 1.38× | — | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | 1.28× | — | ||
| Q1 24 | 1.44× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $1.5B |
| Free Cash FlowOCF − Capex | $3.1B | $1.0B |
| FCF MarginFCF / Revenue | 39.4% | 6.6% |
| Capex IntensityCapex / Revenue | 2.6% | 3.5% |
| Cash ConversionOCF / Net Profit | 1.52× | 1.06× |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | $4.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3B | $1.5B | ||
| Q3 25 | $4.1B | $1.8B | ||
| Q2 25 | $827.0M | $394.0M | ||
| Q1 25 | $1.8B | $2.7B | ||
| Q4 24 | $3.0B | $1.0B | ||
| Q3 24 | $4.3B | $1.6B | ||
| Q2 24 | $1.3B | $737.0M | ||
| Q1 24 | $2.2B | $2.8B |
| Q4 25 | $3.1B | $1.0B | ||
| Q3 25 | $4.0B | $1.3B | ||
| Q2 25 | $720.0M | $-103.0M | ||
| Q1 25 | $1.7B | $2.2B | ||
| Q4 24 | $2.8B | $624.0M | ||
| Q3 24 | $4.2B | $1.1B | ||
| Q2 24 | $1.2B | $318.0M | ||
| Q1 24 | $2.1B | $2.4B |
| Q4 25 | 39.4% | 6.6% | ||
| Q3 25 | 51.0% | 9.2% | ||
| Q2 25 | 10.2% | -0.8% | ||
| Q1 25 | 24.8% | 13.4% | ||
| Q4 24 | 37.4% | 4.4% | ||
| Q3 24 | 55.2% | 7.9% | ||
| Q2 24 | 17.2% | 2.5% | ||
| Q1 24 | 31.6% | 14.4% |
| Q4 25 | 2.6% | 3.5% | ||
| Q3 25 | 1.9% | 3.2% | ||
| Q2 25 | 1.5% | 3.8% | ||
| Q1 25 | 1.6% | 3.1% | ||
| Q4 24 | 1.9% | 3.0% | ||
| Q3 24 | 1.9% | 4.2% | ||
| Q2 24 | 1.9% | 3.4% | ||
| Q1 24 | 1.6% | 2.7% |
| Q4 25 | 1.52× | 1.06× | ||
| Q3 25 | 1.35× | 1.44× | ||
| Q2 25 | 0.42× | 0.38× | ||
| Q1 25 | 1.34× | 1.93× | ||
| Q4 24 | 1.67× | 0.81× | ||
| Q3 24 | 3.44× | 1.48× | ||
| Q2 24 | 0.82× | 0.69× | ||
| Q1 24 | — | 2.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
TJX
| Marmaxx | $9.0B | 60% |
| Home Goods | $2.5B | 17% |
| TJX International | $2.0B | 14% |
| Tjx Canada | $1.5B | 10% |
